Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

The selling price is an indication that the FDA’s planned sunsetting of the rare pediatric disease voucher program may be ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.

Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said the partnership marries DDReg’s expertise in ...

Just three years removed from a lucrative IPO, the company will cut jobs for a third time and invest more heavily in cell ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” ...